Unknown PHASE2 INTERVENTIONAL 2-arm NCT03102723

Platelet Inhibition to Target Reperfusion Injury (PITRI)

Platelet Inhibition to Target Reperfusion Injury: The PITRI Trial

Sponsor: Changi General Hospital

Conditions STEMI

Interventions Cangrelor

Updated 9 times since 2017 Last updated: Apr 19, 2022 Started: Oct 1, 2017 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates STEMI and is currently ongoing. Changi General Hospital leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
May 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
May 2022 — May 2024 [monthly]

Active Not Recruiting PHASE2

Status: Unknown Status → Active Not Recruiting
Jan 2021 — May 2022 [monthly]

Unknown Status PHASE2

▶ Show 4 earlier versions

Nov 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Nov 2018 — Nov 2020 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Nov 2018 [monthly]

Not Yet Recruiting PHASE2
May 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Changi General Hospital
Khoo Teck Puat Hospital
National Heart Centre Singapore
National University Hospital, Singapore
Sengkang General Hospital
Tan Tock Seng Hospital

Data source: National Heart Centre Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore